Switzerland's pharmaceutical industry wants to go green. But new figures reveal that where production happens, the ...

Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, ...

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of trontinemab in participants with ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis The trial ...

Roche Holding AG scrapped long-held global diversity targets for its leadership, showing how pressure from the Trump ...

Amid Trump’s dismantling of DEI, Roche wiped diversity targets from the website of its US subsidiary, Genentech, in mid-February. Basel-based competitor Novartis also said this week it was getting rid ...

ZURICH, March 19 (Reuters) - Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse panels for U.S. hiring, the latest companies ...

Lonza, the Swiss Biotech firm that purchased Vacaville’s Genentech plant from Roche in 2024, released a streamlined operating model and invitations to its Annual General Meeting in Basel, ...

Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the hyper-competitive market for obesity drugs. Morten Lammert will join Roche as its ...

The shareholders approved the total bonuses of the Corporate Executive Committee for the 2024 financial year by 95.00% of votes. They also approved a maximum total future remuneration by 95.15% of ...

Roche Holding AG engages in the pharmaceuticals ... The company was founded in 1896 and is based in Basel, Switzerland.